SCHEMBL4127544

SCHEMBL4127544

CCOC(=O)c1ccc(NC(=O)Nc2ccc(OC)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.78
KMT2A Q03164 6/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
MAPT P10636 8/20 0.74
KDM4E B2RXH2 2/20 0.74
TRPV1 Q8NER1 2/20 0.71
CASP3 P42574 1/20 0.71
SENP7 Q9BQF6 1/20 0.71
GAA P10253 1/20 0.71
CA12 O43570 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69
CA9 Q16790 1/20 0.69
SMN1; SMN2 Q16637 4/20 0.67
RAB9A P51151 2/20 0.67
NPC1 O15118 1/20 0.67
LMNA P02545 2/20 0.65
NPSR1 Q6W5P4 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
CYP1A2 P05177 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9711953 0.90 NPC1 (0.74) MEN1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL4112717 0.88 MAPT (0.76) MEN1KMT2AL3MBTL1MAPTTRPV1
SCHEMBL5412265 0.88 MAPT (0.67) MEN1KMT2AL3MBTL1MAPTCA1
4-Methoxybenzoic Acid Ethyl Ester SCHEMBL203475 0.87 CA1 (0.66) MEN1KMT2AL3MBTL1MAPTCA12
SCHEMBL4122551 0.86 MAPT (0.72) MEN1KMT2AL3MBTL1MAPTTRPV1
SCHEMBL11006378 0.86 MEN1 (0.68) MEN1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL4113307 0.86 MAPT (0.77) MEN1KMT2AMAPTTRPV1CASP3
SCHEMBL28614998 0.85 MAPT (1.00) MEN1KMT2AMAPTKDM4ECA12
4-Methoxybenzoic Acid Ethyl Ester SCHEMBL27605414 0.85 CA1 (0.63) MEN1KMT2AL3MBTL1MAPTCA12
SCHEMBL4922844 0.84 MAPT (0.75) MEN1KMT2AL3MBTL1MAPTTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885KMT2A 2807/4885L3MBTL1 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.